At the beginning of September, the 12 to 15-year-old age group was offered to vaccinate with one dose of the coronavirus vaccine. The Norwegian Institute of Public Health (FHI) analyzed whether this age group was to be offered a 2-dose immunization, but recommended waiting for more knowledge to be gained.
FHI will reassess the situation in early 2022. According to FHI's assessment, there is no reason to offer a second dose of the vaccine to adolescents born in 2006-2009 at this point in time. The rationale for this position is the low risk of serious illness among adolescents.
After the first dose, protection against serious illness reaches 85% and is likely to last for at least 16 weeks. As there are fewer cases of COVID2006 in 2009–19 than among older adolescents, the basis for two doses to limit viral transmission is weaker in this age group.
The second dose of the vaccine also has a higher risk of developing pericarditis and myocarditis, especially in younger men and boys. Analyzes carried out in the Nordic countries will provide detailed information on this risk in the coming time.
We are waiting for the 2nd dose for 12-15 year olds
In early 2022, the FHI will re-examine this issue based on new understanding of serious side effects, disease progression, and overall situation, before possibly making a recommendation for a second dose for this age group. 70% of 12-15 year olds were vaccinated with one dose. The 12-15 age group has 260 people, or 000 percent of the population. Three years are lower secondary school years (4,8, 2008 and 2007), one year is the year of primary school (2006).
Source: IMDi
